Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30598272 | 0.86 | HRH2 (0.41) | KDM4ES1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL27393425 | 0.86 | HRH2 (0.41) | KDM4ES1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL24960426 | 0.86 | HRH2 (0.41) | KDM4ES1PR1S1PR3S1PR5S1PR4 | |
| SCHEMBL19606301 | 0.83 | S1PR1 (0.60) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL22096471 | 0.83 | S1PR1 (0.60) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL22096478 | 0.83 | S1PR1 (0.60) | S1PR1S1PR3S1PR5S1PR4SIGMAR1 | |
| SCHEMBL14968300 | 0.81 | ALDH1A1 (0.41) | KDM4ES1PR1S1PR3S1PR5DRD2 | |
| SCHEMBL7858206 | 0.80 | KDM4E (0.40) | KDM4ES1PR1S1PR3S1PR5DRD2 | |
| SCHEMBL9288623 | 0.80 | KDM4E (0.42) | KDM4ES1PR1S1PR3S1PR5DRD2 | |
| SCHEMBL16106910 | 0.79 | S1PR1 (0.36) | S1PR1S1PR3S1PR5S1PR4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| US-11813260-B1 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| WO-2023171736-A1 | MEDICINE CONTAINING VITAMIN D DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE THEREOF, USED IN COMBINATION WITH IMMUNOMODULATORY SUBSTANCE | 帝人ファーマ株式会社 | 2023-09-14 | — | — | WO | disclosed |
| US-11344546-B2 | Benzamide compounds | Recurium IP Holding, LLC (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022059684-A1 | VITAMIN D DERIVATIVE HAVING CYCLIC AMINE IN SIDE CHAIN | 帝人ファーマ株式会社 | 2022-03-24 | — | — | WO | disclosed |
| EP-3784666-B1 | ANTIPROLIFERATION COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2022-03-16 | — | — | EP | disclosed |
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | SERVIER PHARMACEUTICALS LLC | 2021-11-18 | — | — | US | disclosed |
| WO-2021067215-A1 | PIPERIDINE COMPOUNDS AS MENIN INHIBITORS | AGIOS PHARMACEUTICALS, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20210009543-A1 | BENZAMIDE COMPOUNDS | ZENO MANAGEMENT, INC. | 2021-01-14 | — | — | US | disclosed |
| WO-2021000925-A1 | PYRROLO [2, 3-b] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-01-07 | — | — | WO | disclosed |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. | 2011-05-05 | — | — | US | disclosed |
| US-7893059-B2 | Thiazolopyrimidine PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7846929-B2 | Using 1-(4-((2-(aminopyrimidin-5-yl)-4-morpholinothieno(3,2-d)pyrimidin-6-yl)methyl)piperazin-1-yl)-2-(methylsulfonyl)ethanone; lipid kinase inhibitor; anticancer agents ; antiinflammatory agents; antidiabetic agents | GENENTECH, INC. (US) | 2010-12-07 | — | — | US | disclosed |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | GENENTECH, INC. | 2010-12-02 | — | — | US | disclosed |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CHEMOCENTRYX, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PLRAMED LIMITED (GB) | 2008-02-14 | — | — | US | disclosed |
| US-7326723-B2 | Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same | SANOFI-AVENTIS (FR) | 2008-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353610-A1 | SMALL MOLECULE MENIN INHIBITORS | MEN1, BRCA1, KRAS | KDM4E 2679/4885S1PR1 1495/4885S1PR3 1965/4885 |
| US-20110105464-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PI4KB, PIK3CB, PIK3C2B | KDM4E 3752/4885S1PR1 894/4885S1PR3 713/4885 |
| US-11813260-B1 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | KDM4E 1396/4885S1PR1 2663/4885S1PR3 3236/4885 |
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | KDM4E 4855/4885S1PR1 2440/4885S1PR3 1850/4885 |
| US-20080039459-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | PIK3CA, PI4KB, PI4KA | KDM4E 3626/4885S1PR1 1099/4885S1PR3 710/4885 |
| US-20090118275-A1 | THIAZOLOPYRIMIDINE P13K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PI4KB, PI4KA | KDM4E 2963/4885S1PR1 1229/4885S1PR3 1012/4885 |
| US-20210009543-A1 | BENZAMIDE COMPOUNDS | MKI67, TMBIM6, HDAC1 | KDM4E 1396/4885S1PR1 2663/4885S1PR3 3236/4885 |
| US-11344546-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | KDM4E 1396/4885S1PR1 2663/4885S1PR3 3236/4885 |
| US-20100305096-A1 | BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE | PIK3CA, PIK3R2, PIK3CD | KDM4E 4647/4885S1PR1 1437/4885S1PR3 1093/4885 |
| US-20100150831-A1 | MODULATORS OF CXCR7 | CXCR1, CXCR5, CCR7 | KDM4E 4510/4885S1PR1 713/4885S1PR3 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.